Chad Robins, CEO of Adaptive Biotechnologies.
Anjali Sundaram CNBC
In an interview with CNBC “Closing bell” Barnett said Ark Invest led by Cathie Wood sees major potential for investors in the branch of molecular biology known as genomics, calling it “one of the most transformative investment opportunities of the century.”
Ark’s family of funds includes the Genomic Revolution ETF (ARKG), which seeks to offer investors exposure to areas such as DNA sequencing technology and molecular diagnostics.
ARKG fell by about 7% year on year.
However, in the last 12 months, the ETF has risen approximately 160%. The main leading fund of the company is Ark Innovation ETF (ARKK), which has fallen by about 1.6% so far in 2021. ARKK has also risen by almost 160% in the last 12 months.